Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 5 | 1 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 6 | 1 | 7 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 13 | 5 | 18 |
| 2017 | 114 | 52 | 166 |
| 2018 | 103 | 57 | 160 |
| 2019 | 46 | 20 | 66 |
| 2020 | 4 | 12 | 16 |
| 2021 | 10 | 7 | 17 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Ibrutinib-induced acute kidney injury via interstitial nephritis. Ren Fail. 2021 Dec; 43(1):335-339.
-
Immune thrombocytopenia: options and new perspectives. Blood Coagul Fibrinolysis. 2021 Oct 01; 32(7):427-433.
-
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov; 40(11):4671-4674.
-
Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Expert Rev Hematol. 2021 09; 14(9):819-830.
-
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep; 22(5):693-707.
-
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. Haematologica. 2021 08 01; 106(8):2265-2268.
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct; 99:108012.
-
Molecular Plasticity of Crystalline CK2a' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity. J Med Chem. 2022 01 27; 65(2):1302-1312.
-
Emodin - A natural anthraquinone derivative with diverse pharmacological activities. Phytochemistry. 2021 Oct; 190:112854.
-
Recent advances in drug repurposing using machine learning. Curr Opin Chem Biol. 2021 12; 65:74-84.